CAPITAL IP STARTED WITH A BIG IDEA:
FINANCE PROVEN INNOVATION WITH A DIFFERENT APPROACH
Capital IP is a private investment firm unique in its dual focus on life science and technology credit opportunities. Our ambidextrous approach to investing reflects a broad recognition and appreciation for the critical role intellectual property plays in the successful commercialization of products. We apply our extensive industry expertise to assess the revenue visibility created by these assets and offer a range of creative financing solutions.
A pioneer in providing life science structured credit beginning in 2004, the Capital IP team was the first to introduce flexible structured credit to the technology sector in 2014. Our team was also early to recognize the potential of "non-core" assets beyond drug royalties, acquiring over $300M of branded generics offering predictable cash flows from large pharmaceutical firms and partnering with entrepreneurial teams to successfully manage these brands.
OVER $1.2B INVESTED
BY OUR PARTNERS
BY OUR PARTNERS
40+ LIFE SCIENCE AND TECHNOLOGY INVESTMENTS
OVER A DECADE INNOVATING
We bring over 40 years of collective experience to our investments, including over $1.2B invested within structured credit, milestones and royalties, and the acquisition of legacy assets from some of the world's largest and most well respected pharmaceutical companies. In addition, members of the Capital IP team have played senior roles in executing over $75B of M&A, equity, and debt financings in the life science and technology sectors.
Along the way we've built strong relationships and friendships with entrepreneurial management teams, investors, and executives who acquire and commercialize innovative products and technologies. These relationships offer Capital IP unique insight into the industries, companies, and products where we invest.